Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Vorapaxar in the secondary prevention of atherothrombotic events.

Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KA, Lipka LJ, Liu X, Nicolau JC, Ophuis AJ, Paolasso E, Scirica BM, Spinar J, Theroux P, Wiviott SD, Strony J, Murphy SA; TRA 2P–TIMI 50 Steering Committee and Investigators.

N Engl J Med. 2012 Apr 12;366(15):1404-13. doi: 10.1056/NEJMoa1200933. Epub 2012 Mar 24.

2.

Octreotide in advanced prostatic cancer relapsing under hormonal treatment.

Verhelst J, De Longueville M, Ongena P, Denis L, Mahler C.

Acta Urol Belg. 1994 Apr;62(1):83-8.

PMID:
7515212
3.

Zoladex and flutamide versus bilateral orchiectomy. A randomized phase III EORTC 30853 study. The EORTC GU Group.

Keuppens F, Denis L, Smith P, Carvalho AP, Newling D, Bond A, Sylvester R, De Pauw M, Vermeylen K, Ongena P.

Cancer. 1990 Sep 1;66(5 Suppl):1045-57.

4.

Zoladex and flutamide vs orchidectomy: a phase III EORTC 30853 trial. EORTC Urological Group.

Carvalho AP, de Moura JL, Denis L, Newling D, Smith P, Bono A, Sylvester R, De Pauw M, Ongena P.

Prog Clin Biol Res. 1989;303:129-43. No abstract available.

PMID:
2528736

Supplemental Content

Loading ...
Support Center